Arthralgia Market Report 2026

The arthralgia market size has grown strongly in recent years. It will grow from $5.62 billion in 2025 to $6.09 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing prevalence of joint-related disorders, aging population demographics, rising awareness of musculoskeletal health, expansion of pharmaceutical pain management options, growth of outpatient orthopedic care.

The arthralgia market size is expected to see strong growth in the next few years. It will grow to $8.26 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing demand for personalized treatment regimens, rising adoption of biologic and targeted therapies, expansion of home-based pain management solutions, growing focus on long-term symptom management, increasing investments in joint health research. Major trends in the forecast period include increasing adoption of personalized pain management therapies, rising use of combination treatment approaches, growing focus on early diagnosis of joint disorders, expansion of non-invasive pain relief solutions, enhanced patient-centered treatment models.

The rising prevalence of rheumatoid arthritis is anticipated to drive the growth of the arthralgia market in the coming years. Rheumatoid arthritis is a chronic autoimmune condition that primarily targets the joints, causing inflammation, pain, and potential joint damage. The growing number of rheumatoid arthritis cases is linked to aging populations, genetic susceptibility, lifestyle changes, and environmental factors such as smoking and pollution. Rheumatoid arthritis (RA) leads to arthralgia by inducing chronic joint inflammation, resulting in pain, stiffness, and progressive joint deterioration. For example, in February 2024, according to Arthritis Australia, an Australia-based non-profit organization, arthritis cases in Australia are projected to increase to 5.39 million by 2040 from 4.11 million in 2025, with osteoarthritis rising to 3.11 million from 2.35 million and rheumatoid arthritis reaching 748,721. Hence, the increasing prevalence of rheumatoid arthritis is fueling the growth of the arthralgia market.

Major companies in the arthralgia market are concentrating on developing innovative therapies, such as RMAT-designated gene therapy, to offer patients advanced treatments that provide long-term pain relief and enhanced joint function. RMAT-designated gene therapy refers to a treatment that has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which accelerates the development and review of pioneering gene therapies for serious or life-threatening conditions. For example, in March 2024, Pacira BioSciences Inc., a US-based pharmaceutical company, was granted Regenerative Medicine Advanced Therapy (RMAT) designation for its product PCRX-201 (enekinragene inzadenovec) by the U.S. Food and Drug Administration (FDA). This innovative, intra-articular gene therapy candidate uses a helper-dependent adenovirus (HDAd) to treat knee osteoarthritis. The therapy is designed to produce interleukin-1 receptor antagonists (IL-1Ra). Pacira highlighted its pride in receiving the FDA's first-ever RMAT designation for a gene therapy targeting osteoarthritis and emphasized the encouraging preliminary clinical results that indicate PCRX-201 may serve as a potential disease-modifying treatment.

In November 2023, Nevro Corp., a US-based medical device company, acquired Vyrsa Technologies for $75 million. Through this acquisition, Nevro aims to broaden its chronic pain treatment portfolio by incorporating Vyrsa Technologies’ minimally invasive SI joint fusion devices, improving market reach, and offering advanced solutions for long-term relief in patients suffering from chronic SI joint pain. Vyrsa Technologies is a US-based company operating in the field of arthralgia, with a specific focus on chronic sacroiliac (SI) joint pain.

Major companies operating in the arthralgia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., UCB S.A., Hikma Pharmaceuticals PLC, Ferring Pharmaceuticals, KD Pharma Group S.A., SI-BONE Inc., Xalud Therapeutics Inc., Incannex Healthcare Limited, Cytonics Corporation.

North America was the largest region in the arthralgia market in 2025. The regions covered in the arthralgia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the arthralgia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the arthralgia market by increasing costs of imported pharmaceuticals, diagnostic tools, medical devices, and raw materials used in pain management therapies. Healthcare providers and pharmacies in North America and Europe are most affected due to reliance on global pharmaceutical supply chains, while Asia-Pacific faces cost pressures in drug manufacturing inputs. These tariffs are raising treatment costs and affecting medication affordability. However, they are also encouraging regional drug manufacturing, local sourcing of active ingredients, and diversification of pharmaceutical supply chains.

The arthralgia market research report is one of a series of new reports that provides arthralgia market statistics, including arthralgia industry global market size, regional shares, competitors with a arthralgia market share, detailed arthralgia market segments, market trends and opportunities, and any further data you may need to thrive in the arthralgia industry. This arthralgia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Arthralgia is the pain experienced in one or more joints, often occurring without inflammation, and may arise from different causes such as infections, autoimmune disorders, or injuries. It is considered a symptom rather than a disease, usually pointing to an underlying health problem affecting the joints.

The primary causes of arthralgia include osteoarthritis, rheumatoid arthritis, gout, psoriatic arthritis, lupus, injuries, infections, and other contributing factors. Osteoarthritis is a degenerative joint condition that develops when the protective cartilage cushioning the ends of the bones gradually deteriorates over time. A variety of treatments are available, including medications, therapies, surgical procedures, and lifestyle or home remedies. These treatments can be administered through multiple routes, such as oral, injectable, topical, and transdermal methods. They are supplied through different channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by various end users, such as hospitals, clinics, home care settings, and rehabilitation centers.

The arthralgia market consists of revenues earned by entities by providing services such as diagnosis services, treatment services, physical rehabilitation programs, and supportive services. The market value includes the value of related goods sold by the service provider or included within the service offering. The arthralgia market also includes sales of musculoskeletal diagnostic tools, biologic drugs, anti-inflammatory drugs, and regenerative therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.